Anthracyclines

03/01/2009 - "Anthracyclines are among the most active agents for the treatment of breast cancer; their use in combination regimens improves both disease-free and overall survival in patients with breast cancer. "
12/01/2004 - "The survival of breast cancer patients has significantly improved through the treatment with anthracyclines. "
03/01/1998 - "Pgp was expressed in 23.5% (12/51) specimens and the efficacy of anthracyclines was reduced in Pgp-positive breast cancer tissues, although this reduction was low in THP with a statistically significant difference when comparing with DXR and EPIR. "
02/01/2011 - "Anthracycline-containing regimens improve disease-free and overall survival of patients with early breast cancer, but the toxicity, especially the cardiotoxicity, of the anthracyclines make them unattractive in the adjuvant setting. "
10/01/2002 - "In addition, they can be utilized in combination with anthracyclines, which have been shown to provide a slightly better outcome in patients with early-stage breast cancer compared to non-anthracycline-containing regimens. "

08/01/2010 - "Prime examples are the anthracyclines, which are highly efficacious agents for hemopoietic malignancies and solid tumors, but their clinical use is limited primarily by cardiotoxicity. "
08/01/2015 - "Being an important side effect of anthracyclines, cardiotoxicity may limit the efficacy of cancer therapies in the acute phase (i.e. "
01/01/2014 - "Anthracyclines have markedly improved the survival rates of children with cancer. "
06/12/1993 - "Anthracyclines have greatly contributed to improvement in the prognosis of certain cancers, but their beneficial effect is impaired by an unquestionable toxicity affecting notably the heart. "
04/18/2013 - "The therapeutic efficacy of anthracyclines relies on antitumor immune responses elicited by dying cancer cells. "

06/01/2006 - "The widespread use of anthracyclines in childhood leukemia has resulted in an improved long-term prognosis; however, these patients are subsequently at high risk of developing long-term cardiac damage, with studies suggesting as many as 65% of survivors of childhood leukemia will develop cardiac abnormalities. "
01/01/1999 - "Liposomal encapsulation of anthracyclines has been proposed as a way of decreasing toxicity and probably increasing efficacy of these agents, therefore allowing the exploration of high-dose anthracycline therapy in acute leukemias. "
11/01/2006 - "Anthracyclines are effective in the treatment of leukemia, but their use is limited because of cardiotoxicity. "
01/01/2005 - "In the present study, we report that the acquisition of resistance to anthracyclines in two humans, promyeolocytic leukemia HL-60 and eythroleukemia K562 cell lines, results in a restricted maturation process induced by differentiating agents with respect to that exhibited by their corresponding drug-sensitive counterparts. "
02/03/1977 - "Hodgkin lymphocytes was analyzed; the third part deals with studies on macromolecular carriers forcytostatic anthracyclines in human leukemia cells."

07/01/1999 - "A prospective randomized study was conducted to compare the efficacy and toxicity of two anthracyclines for the treatment of patients with acute myelogenous leukemia (AML). "
04/01/1996 - "Initial studies with refractory or resistant acute myelogenous leukemia (AML), with or without anthracyclines, demonstrated a significant antileukemic effect of HIDAC, with about 60 percent of patients achieving a complete response. "
03/01/1996 - "A prospective randomized study was conducted comparing the efficacy and toxicity of two anthracyclines for the treatment of patients with acute myeloid leukemia (AML) between 55 and 75 years. "
01/01/1981 - "Studies with anthracyclines in pediatric acute nonlymphocytic leukemia."
01/01/2015 - "To date, an uptake transporter has not been reported for anthracyclines, a family of chemotherapeutic agents that are used for treating adult patients with acute myeloid leukemia. "

12/01/1997 - "However, this approach has not been proven to improve survival, involves the risk of greater toxicity and drug-related mortality, and patients with reduced clearance of anthracyclines due to hepatic dysfunction from liver metastases may not be suitable candidates. "
11/01/1993 - "Initial disease free interval, presence of liver metastases and use of anthracyclines were significantly related to time to progression. "
02/01/2000 - "Hepatic arterial chemoembolization (CE) with anthracyclines is an effective treatment for progressive liver metastases of digestive endocrine tumours. "
03/01/2001 - "In multivariable analysis three factors remained significant predictors of short survival time: more than 1 site of metastases (p = 0.00003), shorter time to relapse (p = 0.003) and the previous administration of anthracyclines as adjuvant therapy (p = 0.005). "
06/01/1998 - "Fourteen (42%) and 19 (58%) patients had primary and secondary resistance to anthracyclines, respectively; 70% had visceral metastases. "